All In Biotech

Drug Trial Radar · NCT01456052

A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis

Phase 2 Assessment of the Relationship Between Serotonin and Efficacy in Ulcerative Colitis: A Multi-Center Randomized, Double Blind, Placebo-Controlled, Pilot Study to Evaluate Safety and Preliminary Efficacy of Orally Administered LX1606 in Subjects With Acute, Mild to Moderate Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: May 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

59

Actual

Start

Jan 30, 2012

Primary completion

Sep 3, 2013

Study completion Sep 3, 2013

Sponsor

Lead sponsor
Lexicon PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, placebo-controlled, parallel-group, pilot study to evaluate safety and preliminary effectiveness of two blinded dose levels of telotristat etiprate (LX1606) in participants with acute, mild to moderate ulcerative colitis on 5-aminosalicylic acid/mesalamine therapy.

Conditions

  • Ulcerative Colitis

Interventions

  • Telotristat EtiprateDrug

    500 mg telotristat etiprate (LX1606) administered orally.

  • PlaceboDrug

    Matching placebo administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing a Treatment Emergent Adverse EventTime frame: 8 weeks

Locations

24 sites in 4 countries. Site status is shown where the registry gives one.

  • Lexicon Investigational Site

    Little Rock, Arkansas

  • Lexicon Investigational Site

    Anaheim, California

  • Lexicon Investigational Site

    Santa Monica, California

  • Lexicon Investigational Site

    Great Neck, New York

  • Lexicon Investigational Site

    New York, New York

  • Lexicon Investigational Site

    Tulsa, Oklahoma

  • Lexicon Investigational Site

    Houston, Texas

  • Lexicon Investigational Site

    San Antonio, Texas

  • Lexicon Investigational Site

    Ogden, Utah

  • Lexicon Investigational Site

    Sandy City, Utah

  • Lexicon Investigational Site

    Seattle, Washington

  • Lexicon Investigational Site

    Kaunas, Lithuania

  • Lexicon Investigational Site

    Klaipėda, Lithuania

  • Lexicon Investigational Site

    Šiauliai, Lithuania

  • Lexicon Investigational Site

    Vilnius, Lithuania

  • Lexicon Investigational Site

    Vilnius, Lithuania

  • Lexicon Investigational Site

    Krakow, Poland

  • Lexicon Investigational Site

    Lodz, Poland

  • Lexicon Investigational Site

    Sopot, Poland

  • Lexicon Investigational Site

    Warsaw, Poland

  • Lexicon Investigational Site

    Wroclaw, Poland

  • Lexicon Investigational Site

    Wroclaw, Poland

  • Lexicon Investigational Site

    Nitra, Slovakia

  • Lexicon Investigational Site

    Nové Mesto nad Váhom, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.